Interferon-β induction/interferon-α2B plus ribavirin therapy in patients with chronic hepatitis C

International Journal of Clinical Pharmacology Research

Volumn 25, Issue 2, 2005, Pages 71-76

  Kim, K I ^a,b   Sasase, N ^a,b   Taniguchi, M ^a   Mita, K ^a,b   Kinoshita, K ^b   Togitani, T ^b   Shikata, M ^b   Kimura, N ^b   Izawa, S ^b   Ohtani, A ^b   Nakao, K ^b   Muramoto, Y ^b   Kim, S R ^b   Nabeshima, S ^c   Ishii, F ^c   Tanaka, K ^c   Hayashi, Y ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOBE ASAHI HOSPITAL   (Japan)

^c OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; INTERFERON INDUCTION; MALE; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; AGED; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; INTERFERON-BETA; MALE; MIDDLE AGED; RIBAVIRIN; RNA, VIRAL;

EID: 22444445435     PISSN: 02511649     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Hu K.Q., Vierling J.M., Redeker A.G. Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. J. Viral. Hepat., 8, 1, 2001.
2. Shiratori Y., Kato N., Yokosuka O., Prediction of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology, 113, 558, 1997.
3. Nakamura H., Ito H., Ogawa H., et al. Initial daily interferon administration can gain more eradication of HCV-RNA in patients with chronic hepatitis C, especially with serum intermediate viral load. Hepato- gastroenterol., 46, 1131, 1999.
4. Chayama K., Suzuki F., Tsubota A., et al. Evaluation of quantitative measurements of hepatitis C virus RNA to predict sustained response to interferon by genotype. J. Virol. Methods, 95, 33, 2001.
5. McHutchison J.G., Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin. Liver Dis., 19(Suppl.), 57, 1999.
6. Pol S., Nalpas B., Bourliere M., et al. Combination of ribavirin and interferon alpha surpasses high dose of interferon-alpha alone in patients with genotype-1b-related chronic hepatitis C. Hepatology., 31, 1338, 2000.
7. Okushin H., Morii K., Kishi F., Yuasa S. Efficacy of the combination therapy using twice-a-day IFN-β followed by IFN-α2b in the treatment for chronic hepatitis C. Acta. Hepatol. Jpn., 38, 11, 1997.
8. Fujiwara K., Mochida S., Matsuo S., Ogata I., Hayashi S., Sato Y. Randomized control trial of interferon-β injection at 12-h intervals as a therapy for chronic hepatitis C. Hepatol. Res., 12, 240, 1998.
9. Watanabe H., Iwata K., Sohda T., Sakisaka S. Interferon beta induction/interferon alpha therapy in patients with interferon-resistant chronic hepatitis C. Hepatol. Res., 24, 355, 2002.
10. Poynard T., Marcellin P., Lee S.S., et al. Randomized trial of interferon α2b plus ribavirin for 48 weeks or 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet, 352, 1426, 1998.
11. Neumann A.U., Lam N.R, Dahari H., Gretch D.R., Wiley T.E., Layden T.J., Perelson A.S. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science, 282, 103, 1998.
12. Ampurdanes S., Olmedo E., Maluenda M.D., et al. Persistent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum. J. Hepatol., 25, 827, 1996.
13. Orito E., Mizokami M., Suzuki K., et al. Loss of serum HCV-RNA at week 4 of interferon alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis C. J. Med. Virol., 46, 109, 1995.
14. Lee W.M., Reddy R., Tong M.J., et al. Early hepatitis C virus - RNA responses predict interferon treatment outcomes in chronic hepatitis C. Hepatology, 28, 1411, 1998.
15. Izumi N., Ashina Y., Kurosaki M., et al. A comparison of the exponential decay slope between PEG-IFN alfa-2b/ribavirin and IFN alfa-2b/ribavirin combination therapy in patients with chronic hepatitis C genotype 1b infection and a high viral load. Intervirology, 47, 102, 2004.
16. Anonymous. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C. Hepatology, 36, S3, 2002.
17. Anonymous. Consensus conference. Treatment of Hepatitis. Agence Nationale d'Accreditation et d'Evaluation en Sante (ANAES). Gastroen. Clin. Biol., 26, B303, 2002.
18. Yoshioka K., Yano M., Hirofuji H., et al. Randomised controlled trial of twice-a-day administration of natural interferon for chronic hepatitis C. Hepatol. Res., 18, 310, 2000.
19. Shiratori Y., Perelson A.S., Weinberger L., et al. Different turnover rate of hepatitis C virus clearance by different treatment regimen using interferon-beta. J. Hepatol., 33, 313, 2000.
20. Glue P., Rouzeir-Panis R., Raffanel C., et al. A dose-ranging study of pegylated interferon alpha-2b and ribavirin in chronic hepatitis C. Hepatology., 32, 647, 2000.